Immunopotentiators in Modern Vaccines

Immunopotentiators in Modern Vaccines, Second Edition, provides in-depth insights and overviews of the most successful adjuvants, those that have been included in licensed products, also covering the most promising technologies that have emerged in recent years. In contrast to existing books on the subject, the chapters here provide summaries of key data on the mechanisms of action of the individual vaccine adjuvants.In addition, the book covers key aspects of how the technologies might be further developed and what might be their limitations, while also giving an overview of what made the most advanced adjuvant technologies successful.- Provides contributions from leading international authorities in the field- Features immunopotentiators classified by function, with well-illustrated, informative figures presenting the interaction between the immunopotentiators and the host immune system- Lists advantages and potential hurdles for achieving a practical application for each specific immunopotentiator- Offers US FDA perspectives which highlight how future adjuvants will be approved for new generation vaccines

About the Author

Dr. Virgil E.J.C. Schijns is special guest Professor in Cell Biology & Immunology group, Wageningen University, 6708 WD Wageningen, The Netherlands. Dr. Schijns received his PhD degree at Utrecht University in 1990. Recent professional appointments are Chief Scientific Officer at ERC in Belgium and The Netherlands, (2011 to present); Chief Technology Officer, Vice President at a small biotech spin-off from Utrecht University (2008 to 2011); Special Professor, Immune Intervention, Wageningen University and Research Center (2008 to present); Special Professor in Immunology and Virology at North Carolina State University (NCSU), Raleigh. Department of Population Health and Pathobiology (2002 to present) and Head of Department for Vaccine Technology and Immunology (VTI), AKZO NOBEL (1999 to 2008).

Dr. Derek T. O’Hagan is a formulation scientist and vaccine adjuvant expert with extensive industry experience. He served as Global Head of Vaccine Chemistry and Formulation Research at Novartis Vaccines before its acquisition by GSK. With a background in pharmacy from the UK, he has worked in vaccine delivery research since 1993, including academic roles at the University of Nottingham. Dr. O’Hagan has led research on adjuvants such as MF59, now licensed in flu vaccines in over 40 countries. He has authored over 140 research publications, 60+ patents, and numerous book chapters. Recognized for innovation, he received the Royal Pharmaceutical Society’s Conference Science Medal and the Controlled Release Society’s Young Investigator Award. His work focuses on adjuvant development, nucleic acid vaccines, and needle-free delivery systems, making him a leading figure in vaccine formulation science.